UK markets closed

AMAG Pharmaceuticals, Inc. (AMAG)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
13.67+0.01 (+0.07%)
At close: 4:00PM EDT

AMAG Pharmaceuticals, Inc.

1100 Winter Street
Waltham, MA 02451
United States
617 498 3300
http://www.amagpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees440

Key executives

NameTitlePayExercisedYear born
Dr. William K. HeidenCEO, Pres & Director1.28MN/A1960
Mr. Anthony CascianoExec. VP & COO625.19kN/A1977
Mr. Joseph D. VittiglioExec. VP, Gen. Counsel, Chief Bus. Officer & Corp. Sec.672.28kN/A1972
Mr. Scott D. Myers M.B.A.Pres, CEO & DirectorN/AN/A1966
Mr. Brian PiekosExec. VP & CFON/AN/A1974
Ms. Linda S. LennoxVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Amit VermaVP of MarketingN/AN/AN/A
Ms. Kelly SchickSr. VP, Chief HR Officer & Head of Corp. EngagementN/AN/AN/A
Dr. Laura Williams M.D., M.P.H.Sr. VP of Clinical Devel.N/AN/AN/A
Mr. Peter BawinSr. VP & GM of Cord Blood RegistryN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Corporate governance

AMAG Pharmaceuticals, Inc.’s ISS governance QualityScore as of 6 October 2020 is 4. The pillar scores are Audit: 10; Board: 4; Shareholder rights: 1; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.